GENE ONLINE|News &
Supreme Court Rejects Juno, Welcomes Amgen Back to Patent Discussions
In an eventful week for pharma, the U.S. Supreme Court denied Juno Therapeutics’ request to reinstate a $1.2 billion award from Kite in a patent dispute. The Supreme Court also announced it would listen to Amgen’s bid to revive the patents for a cholesterol drug, Repatha, after a lawsuit with Sanofi and Regeneron.
It's free! Log in now to read
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
